Supernus Pharmaceuticals, Inc. (0LB2.L)
USD 32.03
(1.88%)
USD 32.03
(1.88%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -33.52 Million USD | -109.72% |
| 2022 | 344.84 Million USD | 58.83% |
| 2021 | 217.11 Million USD | 113.51% |
| 2020 | 101.69 Million USD | -47.64% |
| 2019 | 194.22 Million USD | 41.55% |
| 2018 | 137.21 Million USD | 286.02% |
| 2017 | -73.76 Million USD | 14.19% |
| 2016 | -85.95 Million USD | -56.28% |
| 2015 | -55 Million USD | -16.06% |
| 2014 | -47.38 Million USD | 0.86% |
| 2013 | -47.79 Million USD | 27.15% |
| 2012 | -65.61 Million USD | -244.27% |
| 2011 | -19.05 Million USD | -137.18% |
| 2010 | 51.26 Million USD | 17.58% |
| 2009 | 43.59 Million USD | 97.05% |
| 2008 | 22.12 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -12.11 Million USD | 43.07% |
| 2024 Q3 | -2.74 Million USD | 153.5% |
| 2024 Q1 | -21.27 Million USD | 36.55% |
| 2023 Q2 | 17.49 Million USD | -96.19% |
| 2023 Q1 | 458.93 Million USD | 33.08% |
| 2023 Q4 | -33.52 Million USD | 36.34% |
| 2023 FY | -33.52 Million USD | -109.72% |
| 2023 Q3 | -52.66 Million USD | -401.11% |
| 2022 Q4 | 344.84 Million USD | 5.79% |
| 2022 FY | 344.84 Million USD | 58.83% |
| 2022 Q1 | 330.69 Million USD | 52.31% |
| 2022 Q2 | 271.6 Million USD | -17.87% |
| 2022 Q3 | 325.97 Million USD | 20.02% |
| 2021 Q2 | 182.75 Million USD | 31.55% |
| 2021 Q4 | 217.11 Million USD | 10.34% |
| 2021 Q1 | 138.92 Million USD | 36.62% |
| 2021 FY | 217.11 Million USD | 113.51% |
| 2021 Q3 | 196.76 Million USD | 7.67% |
| 2020 Q3 | 209.39 Million USD | 5.42% |
| 2020 Q1 | 154.26 Million USD | -20.57% |
| 2020 Q2 | 198.62 Million USD | 28.75% |
| 2020 FY | 101.69 Million USD | -47.64% |
| 2020 Q4 | 101.69 Million USD | -51.44% |
| 2019 Q4 | 194.22 Million USD | -22.78% |
| 2019 FY | 194.22 Million USD | 41.55% |
| 2019 Q1 | 238.35 Million USD | 73.71% |
| 2019 Q2 | 277.4 Million USD | 16.38% |
| 2019 Q3 | 251.53 Million USD | -9.33% |
| 2018 Q1 | -125.91 Million USD | -70.7% |
| 2018 Q4 | 137.21 Million USD | -32.02% |
| 2018 FY | 137.21 Million USD | 286.02% |
| 2018 Q3 | 201.84 Million USD | -29.6% |
| 2018 Q2 | 286.71 Million USD | 327.71% |
| 2017 Q3 | -53.96 Million USD | 41.01% |
| 2017 FY | -73.76 Million USD | 14.19% |
| 2017 Q1 | -56.28 Million USD | 34.51% |
| 2017 Q2 | -91.49 Million USD | -62.54% |
| 2017 Q4 | -73.76 Million USD | -36.68% |
| 2016 FY | -85.95 Million USD | -56.28% |
| 2016 Q4 | -85.95 Million USD | -77.11% |
| 2016 Q3 | -48.53 Million USD | 10.97% |
| 2016 Q2 | -54.51 Million USD | -37.56% |
| 2016 Q1 | -39.63 Million USD | 27.95% |
| 2015 Q4 | -55 Million USD | -10.81% |
| 2015 FY | -55 Million USD | -16.06% |
| 2015 Q1 | -14.1 Million USD | 70.24% |
| 2015 Q2 | -61.02 Million USD | -332.77% |
| 2015 Q3 | -49.63 Million USD | 18.67% |
| 2014 Q1 | 16.1 Million USD | 133.7% |
| 2014 FY | -47.38 Million USD | 0.86% |
| 2014 Q4 | -47.38 Million USD | -320.0% |
| 2014 Q3 | -11.28 Million USD | -167.5% |
| 2014 Q2 | 16.71 Million USD | 3.78% |
| 2013 Q4 | -47.79 Million USD | -228.39% |
| 2013 FY | -47.79 Million USD | 27.15% |
| 2013 Q1 | -49.78 Million USD | 24.13% |
| 2013 Q2 | -43.53 Million USD | 12.55% |
| 2013 Q3 | 37.23 Million USD | 185.52% |
| 2012 Q1 | 13.23 Million USD | 169.42% |
| 2012 Q2 | -19.43 Million USD | -246.88% |
| 2012 FY | -65.61 Million USD | -244.27% |
| 2012 Q4 | -65.61 Million USD | -3090.47% |
| 2012 Q3 | 2.19 Million USD | 111.29% |
| 2011 Q3 | 73.03 Million USD | 0.0% |
| 2011 Q4 | -19.05 Million USD | -126.1% |
| 2011 FY | -19.05 Million USD | -137.18% |
| 2010 FY | 51.26 Million USD | 17.58% |
| 2010 Q3 | 49.74 Million USD | 0.0% |
| 2010 Q4 | 51.26 Million USD | 3.05% |
| 2009 FY | 43.59 Million USD | 97.05% |
| 2009 Q4 | 43.59 Million USD | 0.0% |
| 2008 FY | 22.12 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 67.434% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 205.15% |
| bluebird bio, Inc. | 108.57 Million USD | 130.88% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -271.861% |
| Editas Medicine, Inc. | -87.11 Million USD | 61.515% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 100.261% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 101.598% |
| Myriad Genetics, Inc. | 88.1 Million USD | 138.056% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 100.125% |
| Biogen Inc. | 6.28 Billion USD | 100.533% |
| Nektar Therapeutics | 210.24 Million USD | 115.947% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | -7.4% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 116.927% |
| Imunon, Inc. | -4.69 Million USD | -613.451% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 118.91% |
| Verastem, Inc. | -37.27 Million USD | 10.062% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 100.407% |
| Waters Corporation | 1.96 Billion USD | 101.71% |
| Perrigo Company plc | 3.32 Billion USD | 101.009% |
| Dynavax Technologies Corporation | 106.63 Million USD | 131.441% |
| Illumina, Inc. | 1.21 Billion USD | 102.762% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 581.151% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 70.561% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 123.11% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 566.495% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 108.852% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -372.211% |
| Evolus, Inc. | 63.7 Million USD | 152.626% |
| Adicet Bio, Inc. | -142 Million USD | 76.391% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 8.904% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | -23.716% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 107.309% |
| FibroGen, Inc. | 56.76 Million USD | 159.061% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 102.928% |
| OPKO Health, Inc. | 230.68 Million USD | 114.534% |
| Homology Medicines, Inc. | 18.43 Million USD | 281.846% |
| Geron Corporation | 14.76 Million USD | 327.132% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 102.115% |
| Exelixis, Inc. | -73.05 Million USD | 54.104% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 38.206% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 77.8% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 69.904% |
| Zoetis Inc. | 4.76 Billion USD | 100.704% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 83.221% |
| Abeona Therapeutics Inc. | -10.07 Million USD | -232.906% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 99.649% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | -130.078% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 103.18% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 103.462% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 75.239% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 102.428% |
| Blueprint Medicines Corporation | 702.83 Million USD | 104.77% |
| Insmed Incorporated | 721.62 Million USD | 104.646% |
| TG Therapeutics, Inc. | 17.86 Million USD | 287.7% |
| Incyte Corporation | -3.17 Billion USD | 98.944% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 104.378% |